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In recent years attention has been focused on the role played by the parasympathetic nervous system in non-antigenic and antigenic-induced bronchoconstriction. Studies carried out in laboratory animals and in asthmatic and chronic bronchitic patients (Hume and Rhys, 1961; Sterling, 1967; Simonsson, Jacobs, and Nadel 1967; Yu, Galant, and Gold, 1972) have shown that stimulation of irritant receptors by citric acid, charcoal dust, cold air, histamine aerosol, cigarette smoke, rapid respiratory manoeuvres or antigen challenge result in bronchoconstriction, and that this reflex bronchoconstriction is largely blocked by atropine.
Atropine has long been used to inhibit salivary and bronchial secretion and, indirectly, laryngospasm before administration of an anaesthetic (Eger, Kraft, and Keasling, 1961; Freeman and Bachman, 1959; Pohto and Ahtee, 1966) . Organ culture studies carried out with human bronchial explants (Sturgess and Reid, 1972a and b) have shown that atropine reduces the secretory activity of mucous and serous glands, although complete inhibition was not achieved.
Since the beginning of the 19th century (Sigmond, 1836) atropine has been used, either alone or in combination with other bronchodilators, in the treatment of reversible airways obstruction (Beakey et al., 1949; Dautreband and Heymans, 1959; Chamberlain, Muir, and Kennedy, 1962; Yu et al., 1972) but the reports that it slows mucous transport rate and ciliary beating (Blair and Woods, 1969) and may alter the physical properties of the mucus layer (Basch, Holinger, and Poncher, 1941) have restricted its clinical use.
It has been widely accepted that atropine increases the viscosity of bronchial secretion and impairs the ciliary clearing, thus causing retention of mucus and airways obstruction, but there is little evidence to support this. The effect of atropine on bronchial secretions of bronchiectatic patients was studied during bronchoscopy (Basch et al., 1941) and less, but more viscous, secretion adherent to the bronchial mucosa was reported. Blanshard (1960) reported no change in sputum viscosity in postoperative patients with chronic bronchitis before or after atropine.
Our study was designed to assess the effect of atropine on sputum volume, viscosity, and chemical constituents in a group of patients with airflow obstruction from various causes.
PATIENTS AND METHODS
Nine male patients who complained of constant cough and sputum were studied; their ages ranged from 18 to 80 years, the mean being 46-2 years (Table I ). Five of these had asthma, two had bronchiectasis, and two had chronic bronchitis (Medical Research Council, 1965) .
The patients were selected because they produced sputum rather than for the underlying 543 cause of this. Since patients 1, 7, and 8 produced three days before treatment. The sputum proover 100 ml of sputum daily, they were con-duced from 06.00 to 15.00 hours was used for sidered to have bronchorrhoea also (Keal, 1971 ; viscosity and chemical studies, using a FerrantiLopez-Vidriero et al., in preparation); bron-Shirley viscometer, over a shear rate of 0-1800 chorrhoea was associated with intrinsic asthma sec-1. in two patients and with bronchiectasis in one.
The remainder of the sputum was frozen at
Atropine was administered by inhalation in -200C and stored at the same temperature until three patients (via a Wright's nebulizer), by intra-chemical analysis was carried out. Preliminary muscular injection in five patients, and orally in treatment of sputum included boiling at 100°C one patient (Table I) . The inhaled and intra-for 10 minutes to destroy salivary and bacterial muscular atropine was administered between enzymes (neuraminidase and aldolase) and dialysis 09.30 and 10.00 hours on the treatment day. (Visking tube 18/32) against distilled water at Atropine methonitrate was used for inhalation, 4°C for 72 hours. The following chemical estimaand atropine sulphate for oral and intramuscular tions were carried out: macromolecular material administration. If the patient did not have a dry (Warren, 1959) , N-acetyl-neuraminic acid (Warmouth or a greater than 10% rise in pulse rate ren, 1959), and methyl-pentose-fucose (Gibbons, after the first dose of atropine, the dose was 1955). doubled the next day (patients 2 and 7, Table I ) and, in this way, atropine effect was induced in every patient. Patient 5 was studied as an out-RESULTS patient and did not have his pulse rate recorded. VOLUME The mean values for the 24-hour and Patient 1 had long-term oral atropine.
three-hour sputum volumes after atropine treatment were compared with mean values obtained SPUTUM STUDIES The daily sputum volume was during control days. Two patients (3 and 9, Table measured, and sputum samples were collected at II) failed to produce any sputum in the three three-hour intervals from 06.00 to 21.00 hours on hours after intramuscular atropine sulphate the day of atropine administration and two or (0-6 mg) but, in both, the amount expectorated (Table II) .
VISCOSITY AND CHEMICAL RESULTS Neither viscosity nor chemical constituents were consistently affected by atropine (Tables II and III) . For each individual patient the levels for apparent viscosity at a shear rate of 1350 sec' and for chemical constituents-dry weight, neuraminic acid, and fucose concentration-fell within the range for their disease group. In two patients (4 and 7, Table 11 ) the apparent viscosity increased on the second day of atropine administration, and in patient 7 it coincided with an increase in the dose of atropine.
There was no significant difference, even at the 10% level, between the results obtained for sputum volume, viscosity, and chemical constituents for the corresponding periods on control and treatment days, nor was there any significant difference before and after treatment on the treatment day itself.
RESPONSE OF BRONCHORRHOEA TO LONG-TERM ATRO-PINE In patient I (Table II) the effect was noted after long-term atropine. He had been receiving corticosteroid treatment, 10 mg/day, for the previous five years. Two months before atropine was started, prednisone had been increased to 35 mg daily and he was also given beclomethasone dipropionate, 200 ug four times a day, but no effect on sputum volume was observed. When oral atropine was started, prednisone was increased to 60 mg daily but then gradually reduced to only 10 mg.
Atropine was started at a dose of 0-3 mg twice daily and was gradually increased during the five weeks study period to 0-6 mg four times a day ( Figure) . The 24-hour sputum volume showed a marked reduction during the last three weeks of the study when atropine levels were at their highest and prednisone levels at their lowest. 
DISCUSSION
Our study confirms Blanshard's (1960) findings since viscosity and also dry weight yield, neuraminic acid, and fucose varied little after atropine.
Since studies of the human bronchial glands in organ culture (Sturgess and Reid, 1972a have shown that atropine has a depressant effect on the secretion from both mucous and serous cells of the submucosal glands, it is somewhat surprising that our studies revealed practically no effect on the volume and constituents of secretion. On the other hand, organ culture studies also showed that gland hypertrophy affects sensitivity to drugs; that is, the larger the gland-expressed as a gland/wall ratio (Reid, 1960 -the less the inhibitory effect of a given dose of atropine.
The two patients in whom secretion dried up produced small amounts of sputum and, presumably, had little if any gland hypertrophy: both complained of marked dryness of the mouth. It seems that in these patients the effect of atropine was mainly on the salivary secretion, thus affecting the expulsion of bronchial secretion by reducing the 'lubricating action' of saliva, as reported by Hillis (1952) . The reduction in sputum volume observed in one patient with 'bronchorrhoea' associated with bronchiectasis could also be explained by the inhibitory effect of atropine on salivary secretion since our studies showed that most of the 'sputum' produced had chemical and rheological characteristics of saliva.
The features of the response of the patient with bronchorrhoea to long-term atropine are different from the pattern of response to prednisone described by Keal (1971) . In some of Keal's patients with bronchorrhoea associated with asthma, a fall in sputum volume was accelerated by prednisone, and the concentration of dry weight and neuraminic acid suggested an increased concentration of the secretion, perhaps by altering the tissue fluid component. In the present study the decrease in sputum volume after atropine, without any change in chemical constituents, suggests an inhibitory effect on bronchial gland secretion. Since the patient on oral atropine had intrinsic asthma, minimal gland hypertrophy would be expected and this should be susceptible to inhibition by atropine. It seems that excessive bronchial secretion may be of two types-one susceptible to atropine and the other to prednisone.
